



Contact:

Staph Bakali
Genocea Biosciences
617.876.8191
Staph.Bakali@genocea.com

GENOCEA BIOSCIENCES NAMES ROBERT E. FARRELL, JR VICE PRESIDENT FINANCE AND ADMINISTRATION

Cambridge, MA – June 19, 2009 – Genocea Biosciences, a leading vaccine discovery and development company, today announced that Robert E. Farrell Jr., CPA .has joined the company as Vice President of Finance and Administration.

“As we continue to progress our pipeline and execute on our business plan, we have been anticipating the future needs of the company, said Staph Leavenworth Bakali, Genocea’s Chief Executive Officer. “Bob’s financial and administrative experience working in the biotech start-up companies along with experience in public company financial reporting will be invaluable to Genocea as we continue to grow”.

“Genocea is a unique player in the vaccine space. I am delighted to be joining Genocea at such an exciting time and look forward to helping the company achieve its growth objectives” said Bob Farrell.

Bob joins Genocea from Magen Biosciences which was recently acquired by Pharmaceutical Product Development (PPD) where he was responsible for all financial, treasury and administrative functions. Prior to that, Bob held senior financial positions at Oscient Pharmaceuticals and NeoGenesis Pharmaceuticals where he played a key role in building and directing all financial reporting and treasury efforts, including an initial public offering and SEC filings. Bob is a licensed CPA and a graduate of Bentley College.

About Genocea Biosciences:

Genocea Biosciences was founded in 2006 to commercialize key breakthroughs in vaccine discovery and development. The company’s proprietary T cell-directed antigen discovery program represents a broad platform with the potential to generate significant novel vaccines for multiple pathogens with high unmet medical need. Genocea is currently developing vaccines for *chlamydia trachomatis* (a sexually transmitted disease with an estimated 90 million cases worldwide), *streptococcus pneumoniae* (pneumonia is the leading killer of children under the age of five worldwide) and other undisclosed targets. In 2008, Genocea was selected as “Best Vaccine Startup” at the World Vaccine Congress and was selected one of the 15 most exciting biotech startup companies by FierceBiotech. Genocea is backed by leading investors including Lux Capital Management, Polaris Venture Partners, Morningside Ventures, SR One, Auriga Partners, Cycad Group and Alexandria Real Estate Equities. Visit www.genocea.com for more information